通过LC-MS/MS确定Codonopsis Pilosula的四个活性成分的药理动力学和相关的性别差异研究
Hongfei Mu1, Qiong Jin2, Jia Tang1
1Department of Drug Metabolism, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 100050, Beijing, PR China.
Journal of ethnopharmacology
|October 5, 2024
概括
这项研究研究了大鼠中的四种Codonopsis pilosula成分的药理动力学,揭示了Atractylenolide III吸收和代谢的显著性别差异. 这些发现支持个性化C. pilosula治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 药物新陈代谢 药物新陈代谢
背景情况:
- (Codonopsis pilosula) 是一种传统的中国草药,用于免疫,消化和循环支持.
- 现有的C. pilosula的药理动力学研究仅限于单个成分,缺乏性别特定的分析.
- 这项研究解决了了解多种C. pilosula活性成分和潜在的性别变异的同时药理动学的需要.
研究的目的:
- 在大鼠口服后,对C. pilosula的四个主要活性成分的药理动力学特征进行鉴定.
- 阐明这些成分在吸收和代谢中的性别差异的潜在机制.
- 提供支持C. pilosula.个性化治疗应用的数据.
主要方法:
- 建立并验证了一种敏感的LC-MS/MS方法,用于同时量化大鼠血中的四个C. pilosula成分.
- 向雄性和雌性大鼠口服C. pilosula酒精提取物,并分析了血度.
- 在体外研究了肠道透性和肝脏微小体的代谢稳定性,以评估与性别相关的药物动力学变化.
主要成果:
- 四个活性成分,包括Atractylenolide III,Lobetyolin,Tangshenoside I和Syringin,被迅速吸收. 这些活性成分被迅速吸收.
- 与雄性相比,雌性大鼠暴露 (AUC) 和Atractylenolide III的峰值度 (Cmax) 显著更高.
- 在女性中,阿特拉基列胺III的药理动力学上的性别差异归因于肠道吸收增加和肝脏代谢减少.
结论:
- 开发了一种可靠的LC-MS/MS方法,用于分析大鼠血中的关键C. pilosula成分.
- 在Atractylenolide III的药理动力学中观察到显著的性别差异,受肠道吸收和肝脏代谢的影响.
- 这些发现为C. pilosula的合理临床使用提供了关键的见解,强调了个性化的治疗方法.
相关概念视频
00:54Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
564
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
564
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
349
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
349